2024
Comparing frequency of booster vaccination to prevent severe COVID-19 by risk group in the United States
Park H, Gonsalves G, Tan S, Kelly J, Rutherford G, Wachter R, Schechter R, Paltiel A, Lo N. Comparing frequency of booster vaccination to prevent severe COVID-19 by risk group in the United States. Nature Communications 2024, 15: 1883. PMID: 38448400, PMCID: PMC10917753, DOI: 10.1038/s41467-024-45549-9.Peer-Reviewed Original ResearchConceptsSevere COVID-19Risk of severe COVID-19COVID-19 booster vaccinationBooster vaccinationHigh-risk populationAbsolute annual riskWaning of protectionImmunocompromised populationsFrequent boostingOlder age groupsAnnual boosterImmune evasionImmunocompromised personsPublic health needsPublic health guidanceRisk groupsFrequent boostersImmune statusRisk factorsFrequency of booster vaccinationHealth needsHealth guidanceCompare frequenciesAge groupsVaccine
2007
Cost-Effectiveness of HIV Testing and Treatment in the United States
Walensky RP, Freedberg KA, Weinstein MC, Paltiel AD. Cost-Effectiveness of HIV Testing and Treatment in the United States. Clinical Infectious Diseases 2007, 45: s248-s254. PMID: 18190295, PMCID: PMC2365915, DOI: 10.1086/522546.Peer-Reviewed Original ResearchConceptsHIV testingVoluntary human immunodeficiency virus (HIV) testingHuman immunodeficiency virus (HIV) testingRoutine HIV testingVoluntary HIV testingLower cost-effectiveness ratioCost-effectiveness ratioCost-effectiveness studiesHealth care settingsPublic health importanceHealth care interventionsCost-effectiveness analysisImmunodeficiency syndromeRisk factorsCare interventionsUS CentersCare settingsVirus testingHealth effectivenessHealth importanceDisease controlRecent evidenceHIVNew guidelinesUnited States